Bascones-Martínez A, Rodríguez-Gutierrez C, Rodríguez-Gómez E, Gil-Montoya JA, Gómez-Font R, González-Moles MA. Evaluation of p53, Caspase-3, Bcl-2, and Ki-67 markers in oral squamous cell carcinoma and premalignant epithelium in a sample from Alava Province (Spain). Med Oral Patol Oral Cir Bucal. 2013 Nov 1;18 (6):e846-50.

doi:10.4317/medoral.18901

http://dx.doi.org/doi:10.4317/medoral.18901

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
http://dx.doi.org/10.1016/S0092-8674(00)81683-9

2. Choi S, Myers JN: Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008;87:14-32.
http://dx.doi.org/10.1177/154405910808700104

3. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res.1996;56:2488-92.
PMid:8653682

4. Toner M, O'Regan EM: Head and neck squamous cell carcinoma in the young: a spectrum or a distinct group? Part 2. Head Neck Pathol. 2009;3:249-51.
http://dx.doi.org/10.1007/s12105-009-0137-y
PMid:20596980 PMCid:PMC2811629

5. Gasco M, Crook T: The p53 network in head and neck cancer. Oral Oncol. 2003;39:222-31.
http://dx.doi.org/10.1016/S1368-8375(02)00163-X

6. Vogelstein B, Kinzler KW.The multistep nature of cancer. Trends Genet.1993;9:138-41.
http://dx.doi.org/10.1016/0168-9525(93)90209-Z

7. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol. 2000;18:1465-73.
PMid:10735894

8. Howard JD, Lu B, Chung CH. Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation. Oral Oncol. 2012;48:10-7.
http://dx.doi.org/10.1016/j.oraloncology.2011.09.013
PMid:22020057

9. Gonzalez-Moles MA, Ruiz-Avila I, Gil-Montoya JA, Esteban F, Bravo M: Analysis of Ki-67 expression in oral squamous cell carcinoma: why Ki-67 is not a prognostic indicator. Oral Oncol. 2010;46:525-30.
http://dx.doi.org/10.1016/j.oraloncology.2010.03.020
PMid:20400362

10. González-Moles MA, Bravo M, Ruiz-Avila I, Acebal F, Gil-Montoya JA, Brener S, et al.: Ki-67 expression in non-tumor epithelium adjacent to oral cancer as risk marker for multiple oral tumors. Oral Dis. 2010;16:68-75.
http://dx.doi.org/10.1111/j.1601-0825.2009.01611.x
PMid:19682318

11. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74.
http://dx.doi.org/10.2307/2529310

12. Liu SC, Klein-Szanto AJ: Markers of proliferation in normal and leukoplakia oral epithelia. Oral Oncol. 2000;36:145-51.
http://dx.doi.org/10.1016/S1368-8375(99)00076-7

13. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature. 1991;351:453-6.
http://dx.doi.org/10.1038/351453a0
PMid:2046748

14. Baral R, Patnaik S, Das BR: Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. Eur J Oral Sci. 1998;106:907-13.
http://dx.doi.org/10.1046/j.0909-8836.1998.eos106502.x

15. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799-805.
PMid:8183579

16. Wilson GD, Saunders MI, Dische S, Richman PI, Daley FM, Bentzen SM: Bcl-2 expression in head and neck cancer: an enigmatic prognostic marker. Int J Radiat Oncol Biol Phys. 2001;49:435-41.
http://dx.doi.org/10.1016/S0360-3016(00)01498-X

17. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH: A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63:1727-30.
PMid:12702551